Gene: CRACR2A

84766
EFCAB4B
calcium release activated channel regulator 2A
protein-coding
12p13.32
Ensembl:ENSG00000130038 MIM:614178 Vega:OTTHUMG00000168185 UniprotKB:Q9BSW2
NC_000012.12
SNP Mapped
1   ANCO-SNPs
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.235e-1 (AD)  7.497e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs11062784chr12:3745301 (GRCh38.p7)A>Gnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of CRACR2A gene27153756
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of CRACR2A mRNA24449571
C006632arsenic trioxidearsenic trioxide results in increased expression of CRACR2A mRNA25258189
C006780bisphenol Abisphenol A results in decreased expression of CRACR2A mRNA25181051
C018475butyraldehydebutyraldehyde results in increased expression of CRACR2A mRNA26079696
C118739entinostatentinostat results in increased expression of CRACR2A mRNA27188386
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of CRACR2A mRNA23649840
D005557FormaldehydeFormaldehyde results in decreased expression of CRACR2A mRNA23649840
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of CRACR2A mRNA23649840
C046012pentanalpentanal results in increased expression of CRACR2A mRNA26079696
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of CRACR2A mRNA22714537
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of CRACR2A mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of CRACR2A mRNA27913140
D014212TretinoinTretinoin results in decreased expression of CRACR2A mRNA23724009
D014635Valproic AcidValproic Acid results in increased methylation of CRACR2A gene29154799
D014638VanadatesVanadates results in decreased expression of CRACR2A mRNA22714537

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005509calcium ion binding-IDA20418871  
GO:0005515protein binding-IPI20418871  23088713  25416956  
GO ID GO Term Qualifier Evidence PubMed
GO:0002115store-operated calcium entry-IMP20418871  
GO:0002250adaptive immune response-IEA-  
GO:0032237activation of store-operated calcium channel activity-IMP20418871  
GO:0043312neutrophil degranulation-TAS-  
GO:0051928positive regulation of calcium ion transport-IMP20418871  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS-  
GO:0005737cytoplasm-IDA20418871  
GO:0016020membrane-HDA19946888  
GO:0035580specific granule lumen-TAS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-168249Innate Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-6798695Neutrophil degranulationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal